{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:11:45Z","timestamp":1790691105997,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies, achieving durable remissions in cases refractory to standard therapies. A potentially life-threatening complication is immune effector cell-associated neurotoxicity syndrome (ICANS), which poses significant challenges to clinical management. ICANS encompasses a range of neuropsychiatric symptoms, including delirium, mood disorders, psychosis, seizures, and cerebral edema. The psychiatric dimensions of ICANS remain underreported, and their interplay with neurologic manifestations is poorly understood. This study reviews the psychiatric manifestations of ICANS and presents a case series illustrating its clinical complexity. Methods: A systematic literature search was conducted using PubMed and Google Scholar for studies published between 2020 and 2024. Search terms included \u201cICANS\u201d, \u201cdelirium\u201d, \u201cCAR T-cell\u201d, \u201cneurotoxicity\u201d, and \u201cpsychiatric\u201d. The inclusion criteria included studies published in English that focused on adult patients experiencing neuropsychiatric symptoms of ICANS. Two clinical cases of ICANS with prominent psychiatric features are presented. Results: The literature review found three relevant studies, which emphasized agitation, hypoactivity, and mood disturbances as often-overlooked psychiatric symptoms linked to ICANS. The case series highlights psychiatric manifestations, including delirium, irritability, and cognitive impairment. Recovery was supported through interventions such as corticosteroid tapering, antipsychotic treatment, and multidisciplinary care. Conclusions: ICANS is a multifaceted syndrome with significant neuropsychiatric sequelae that complicate its diagnosis and management. An enhanced recognition of its psychiatric dimensions and interdisciplinary approaches are critical to improving outcomes.<\/jats:p>","DOI":"10.3390\/jcm14051451","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:06Z","timestamp":1740124386000},"page":"1451","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune Effector Cell-Associated Neurotoxicity Syndrome After CAR T-Cell Therapy and Other Psychiatric Manifestations: A Review and Case Series"],"prefix":"10.3390","volume":"14","author":[{"given":"Adela Georgiana","family":"Buciuc","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Jackson Health System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Padilla","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rueda-Lara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelde","family":"Espinel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.psym.2018.10.006","article-title":"Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist","volume":"60","author":"Pawar","year":"2019","journal-title":"Psychosomatics"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Han, M.W., Jeong, S.Y., Suh, C.H., Park, H., Guenette, J.P., Huang, R.Y., Kim, K.W., and Yoon, D.H. (2024). Incidence of Immune Effector Cell-Associated Neurotoxicity Among Patients Treated with CAR T-Cell Therapy for Hematologic Malignancies: Systematic Review and Meta-Analysis. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1392831"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors After Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of Mid-Term (6\u201312 Months) Neurotoxicity in B-Cell Lymphoma Patients Treated with CAR T Cells: A Prospective Cohort Study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Quinn, R., Thakkar, A., Zareef, S., Elkind, R., Wright, K., Fehn, K., Sakalian, S., Abreu, M., De Castro, A., and Mustafa, J. (2021). Neurotoxicity of Axicabtagene Ciloleucel and Long-Term Outcomes in a Minority-Rich, Ethnically Diverse Real-World Cohort. Blood, 138.","DOI":"10.1182\/blood-2021-153917"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003583"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ghemrawi, R., Abuamer, L., Kremesh, S., and Hussien, G. (2024). Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092158"},{"key":"ref_8","first-page":"1","article-title":"Immunotherapy: The Next Frontier in Cancer Treatment\u2014Unlocking the Potential of CAR-Macrophages and Combination Therapies","volume":"1","author":"Shuja","year":"2024","journal-title":"Dev. Medico-Life-Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Georgoudaki, A.M., van Vliet, A.A., Raimo, M., and de Gruijl, T.D. (2021). Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13184722"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.21037\/jtd.2020.03.118","article-title":"CAR-T Cell Therapy for Lung Cancer: A Promising but Challenging Future","volume":"12","author":"Zhong","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Larue, M., Bouvier, A., Maillard, A., Cuffel, A., Allain, V., Ursu, R., Carpentier, A.F., Azoulay, E., Thieblemont, C., and Di Blasi, R. (2024). Neurofilament Light Chain Levels as an Early Predictive Biomarker of Neurotoxicity After CAR T-Cell Therapy. J. Immunother. Cancer, 12.","DOI":"10.1136\/jitc-2024-009525"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell\u2013Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/19418744221128852","article-title":"Continuous EEG Monitoring Detects Nonconvulsive Seizure and Ictal-Interictal Continuum Abnormalities in Moderate to Severe ICANS Following Systemic CAR-T Therapy","volume":"13","author":"Satyanarayan","year":"2023","journal-title":"Neurohospitalist"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hughes, A.D., Teachey, D.T., and Diorio, C. (2024). Riding the Storm: Managing Cytokine-Related Toxicities in CAR-T Cell Therapy. Semin. Immunopathol., 46.","DOI":"10.1007\/s00281-024-01013-w"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinico-Pathologic Correlates, and Future Directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Demosthenous, C., Evangelidis, P., Bousiou, Z., Batsis, I., Vardi, A., Mallouri, D., Koravou, E.-E., Spyridis, N., and Panteliadou, A. (2024). Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011028"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S262566","article-title":"GM-CSF: A Promising Target in Inflammation and Autoimmunity","volume":"9","author":"Lee","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine Release Syndrome and Neurotoxicity Following CAR T-Cell Therapy for Hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Khalid, F., Gupta, R., Gor, R., Gor, D., and Singh, V. (2023). Neurological adverse effects of immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. World J. Neurol., 14.","DOI":"10.14740\/wjon1575"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nasereddin, L., Alnajjar, O., Bashar, H., Abuarab, S.F., Al-Adwan, R., Chellappan, D.K., and Barakat, M. (2024). Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications. Neuropsychopharmacol. Rep., 12.","DOI":"10.3390\/diseases12120300"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ferreros, P., and Trapero, I. (2022). Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. Diseases, 10.","DOI":"10.3390\/diseases10030041"},{"key":"ref_25","first-page":"264","article-title":"Modulating Effect of Cytokines on Mechanisms of Synaptic Plasticity in the Brain","volume":"82","author":"Levin","year":"2017","journal-title":"Biochemistry"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kuznetsova, V., Oza, H., Rosenfeld, H., Sales, C., van der Linde, S., Roos, I., Roberts, S., D'Aprano, F., Loi, S.M., and Dowling, M. (2024). Neuropsychological Outcomes of Patients with Haematological Malignancies Undergoing Chimeric Antigen Receptor T-Cell Therapy: Protocol for a Prospective Study. BMJ Neurol. Open, 6.","DOI":"10.1136\/bmjno-2024-000800"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1451\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:45Z","timestamp":1760027985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051451"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051451","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}